What is deuterated trazodone?
Deuterated trazodone, also known by its investigational name Xywav (or Xyrem in its non-deuterated form), is a central nervous system depressant used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy [1][2]. It is a specific formulation of sodium oxybate, where the hydrogen atoms have been replaced with deuterium, a stable isotope of hydrogen [1]. This isotopic substitution alters the drug's metabolism, leading to a prolonged duration of action [1][3].
How does deuterated trazodone work?
The exact mechanism of action for sodium oxybate, and by extension deuterated trazodone, is not fully understood. However, it is believed to act as a gamma-aminobutyric acid (GABA) receptor agonist [1][2]. GABA is a primary inhibitory neurotransmitter in the brain, and its activation is associated with reduced neuronal excitability, which may help to stabilize sleep and reduce the occurrence of cataplexy [1].
When will the patent for deuterated trazodone expire?
The patent landscape for deuterated trazodone is complex and involves multiple patents protecting different aspects of the drug, including its composition, manufacturing, and methods of use. DrugPatentWatch.com tracks these patents, providing detailed information on their expiration dates. Generally, patents for pharmaceuticals can last up to 20 years from the filing date, but extensions and other forms of market exclusivity can alter the effective market protection period [4].
What are the risks associated with deuterated trazodone?
Deuterated trazodone carries significant risks, including central nervous system depression, abuse, and addiction [1][2]. It is a Schedule III controlled substance, indicating a potential for abuse and dependence [2]. Common side effects can include dizziness, nausea, vomiting, and sleepiness [1]. Due to its depressant effects, it should not be taken with alcohol or other CNS depressants [1][2].
How does deuterated trazodone compare to non-deuterated sodium oxybate (Xyrem)?
Deuterated trazodone (Xywav) is a deuterated form of sodium oxybate, the active ingredient in Xyrem [1][2]. The deuterium substitution in Xywav is designed to slow the drug's metabolism, resulting in a longer half-life and sustained release compared to Xyrem [1][3]. This prolonged action is intended to provide more consistent symptom control throughout the night and day [1].
Can generic versions of deuterated trazodone be made?
The development of generic versions of deuterated trazodone would depend on the expiration of relevant patents and the granting of regulatory approval for a generic product [4]. The complex patent protection surrounding deuterated trazodone may present challenges for generic manufacturers.
What are the regulatory considerations for deuterated trazodone?
Deuterated trazodone is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy [1][2]. Its use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program due to the potential for abuse and misuse [1][2].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/xywav
[2] https://www.drugpatentwatch.com/drug/xyrem
[3] https://www.drugpatentwatch.com/blog/deuterated-drugs
[4] https://www.drugpatentwatch.com/